Nanobiotix S.A. (LON: 0QAV)
London
· Delayed Price · Currency is GBP · Price in EUR
3.110
-0.072 (-2.26%)
Jan 23, 2025, 9:35 AM BST
Nanobiotix Revenue
Nanobiotix had revenue of 9.29M EUR in the half year ending June 30, 2024, with 598.95% growth. This brings the company's revenue in the last twelve months to 42.20M, up 526.17% year-over-year. In the year 2023, Nanobiotix had annual revenue of 36.21M with 658.12% growth.
Revenue (ttm)
42.20M EUR
Revenue Growth
+526.17%
P/S Ratio
n/a
Revenue / Employee
413.76K EUR
Employees
102
Market Cap
127.33M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Nanobiotix News
- 5 weeks ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 6 weeks ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Participate in Multiple Investor Conferences in November - GlobeNewsWire
- 4 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth - GlobeNewsWire
- 5 months ago - Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 8 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire